Form 4: Dynavax CEO Spencer's Equity Vesting Accelerates Amid Sanofi Merger

Dynavax Technologies CEO Ryan Spencer reported accelerated vesting of performance and restricted stock units in connection with the company's merger agreement with Sanofi.

Summary

• Ryan Spencer, CEO and Director of Dynavax Technologies Corp, reported transactions related to his beneficial ownership.
• On December 23, 2025, the Board of Directors approved the acceleration of vesting for certain performance-based restricted stock units (PSUs) and restricted stock units (RSUs) due to a merger agreement with Sanofi.
• PSUs representing 125% of the target number (156,250 shares) were earned based on the achievement of relative Total Stockholder Return (rTSR) performance, with the Issuer's stock valued at $15.50 per share for the merger.
• RSUs totaling 100,333 shares (55,000 from a February 2024 grant and 45,333 from a February 2025 grant) also vested.
• On December 24, 2025, 138,168 shares were withheld by the Issuer at a price of $15.38 per share to satisfy tax withholding requirements on the vested PSUs and RSUs.
• Following these transactions, Spencer beneficially owns 379,620 shares of common stock, which includes 472 shares purchased through the Employee Stock Purchase Plan on August 15, 2025.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the acceleration of equity vesting, the achievement of performance targets at 125%, and the context of a merger agreement which typically provides a premium for shareholders.

Positives

• Acceleration of vesting for performance-based restricted stock units (PSUs) and restricted stock units (RSUs) due to the merger agreement.
• PSUs were earned at 125% of the target number, indicating strong performance relative to peers.
• The merger agreement values Dynavax common stock at $15.50 per share.

Negatives

• 138,168 shares were withheld by the Issuer to satisfy tax withholding requirements, reducing the net shares received.

Future Outlook

The filing indicates that Dynavax Technologies Corp is subject to an Agreement and Plan of Merger with Sanofi, suggesting the company will be acquired, leading to a change in its corporate structure and ownership.

Management Comments

• The Board of Directors approved the acceleration of vesting for PSUs and RSUs in connection with the merger agreement.
• The Board determined that PSUs were earned at 125% of the target number based on rTSR performance over a shortened period, using the merger price of $15.50 per share.

Industry Context

This transaction occurs within the context of a merger agreement where Dynavax Technologies Corp is being acquired by Sanofi, a major pharmaceutical company. Such acquisitions are common in the biotechnology and pharmaceutical sectors, often driven by strategic portfolio expansion or access to specific technologies/products.

Corporate Governance

Stakeholder Impact

• Shareholders: The merger agreement implies a specific value ($15.50 per share) for their holdings, likely representing a premium.
• Employees (specifically Ryan Spencer): Benefits from accelerated vesting of equity awards, realizing value from past performance and future potential tied to the merger.

Next Steps

• Completion of the merger between Dynavax Technologies Corp and Sanofi.

Key Dates

Keywords

Dynavax Technologies, DVAX, Ryan Spencer, SEC Form 4, Insider Trading, Stock Vesting, Restricted Stock Units, Performance Stock Units, Merger Agreement, Sanofi, Equity Compensation, CEO Compensation